USC study explores if mindfulness meditation enhances psilocybin therapy for depression

Researchers at the University of Southern California have launched a clinical study on psychedelic therapy using psilocybin. The investigation aims to explore whether mindfulness meditation can boost the therapeutic benefits of the treatment. The FDA has already recognised psilocybin as a breakthrough therapy for major depressive disorder and treatment-resistant depression. The study is co-led by Dr. Rael Cahn and Dr. Caryn Lerman, with contributions from experts in cognitive neuroimaging and music neuroscience. It will involve around 72 middle-aged adults from the Los Angeles area, split into two groups: one receiving psilocybin alone and the other receiving psilocybin combined with mindfulness meditation training.

An open-label design ensures full transparency, with both participants and researchers aware of the treatment assignments. Before and after the intervention, extensive assessments will take place, including EEG, MRI/fMRI scans, biological sampling, and psychological tests. Follow-ups at three, six, and twelve months will track the lasting effects of the treatment.

Psilocybin is known to alter sensory processing, time perception, and self-aware cognition, often leading to deep spiritual experiences. The project is funded by a grant from ARPA-H under its EVIDENT initiative, supporting rapid-acting mental health treatments. The study will provide detailed insights into the combined effects of psilocybin and mindfulness meditation. Findings could influence future approaches to treating depression. Long-term follow-ups will determine how durable the benefits may be.